Study to examine the association between fasting glucose and mortality by age in patients with diabetes.

Is preventive medication the key to reducing risk of fractures, VTEs, and sepsis?

Systematic review and meta-analysis show lead in HbA1c reduction, weight loss, and favorable fasting blood glucose levels.

Patients with type 1 diagnosed with depression said to be in danger of experiencing more severe episodes of hypoglycemia and hyperglycemia.

A 39-year-old, overweight (BMI 27 kg/m2) patient comes into your office for his annual wellness examination. Routine labs show random plasma glucose of 176 mg/dL, so you ask him to return for a fasting plasma glucose and A1C. The results show a FPG 139 mg/dL and A1C of 7.7%. He is resistant to the idea of starting medication and is very keen on pursuing a trial period of dietary modifications and an exercise program, especially after you tell him about the benefits of moderate exercise on diabetes. Which of the following statements about exercise is true? A. Exercise reduces basal insulin levels only when paired with proper diet B. Exercise can lead to weight loss, but rarely reduces A1C levels C. Exercise can reduce all-cause mortality by up to 38% D. Exercise must be rigorous and regular to lead to greatest reduction in mortality Follow the link for the answer.

Would you consider using a diabetes software program that can determine the best treatment for type 2 and provide you 3 possible solutions that fit into the patient’s budget using their insurance? Follow the link to see how you and your colleagues compare.

Links between diabetes and cancer: common risk factors

Epidemiologic studies demonstrate that those with diabetes are more likely to develop cancer, but the mechanisms through which this may occur are incompletely understood. The American Diabetes Association and the American Cancer Society published a consensus report in 2010, with the aim of examining the knowledge regarding the association between diabetes and cancer, exploring the risk factors for both conditions, to examine their possible biologic links and to determine whether certain treatments for diabetes modify cancer risk.

Battle between two GLP-1 receptor agonists proves semaglutide achieves favorable HbA1c levels, decreased mean body weight.

Patients who skipped initial treatment with metformin and were instead started on second-line antihyperglycemic medication more likely to need dual therapy or insulin to control T2.

Patient specific considerations have to be taken into account prior to choosing GLP-1 agonist or SGLT2 inhibitor as second-line anti-hyperglycemic agent.